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Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view 
of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective 
treatment options, there is a strong need for the development of more effective treatment 
approaches for patients with MPM. This review will provide a comprehensive state of the art 
of new investigational approaches for mesothelioma. In an introductory section, the etiology, 
epidemiology, natural history, and standard of care treatment for MPM will be discussed. This 
review provide an update of the major clinical trials that impact mesothelioma treatment, discuss 
the impact of novel therapeutics, and provide perspective on where the clinical research in 
mesothelioma is moving. The evidence was collected by a systematic analysis of the literature 
(2000–2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, 
Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA 
Database (International Network of Agencies for Health Technology Assessment – INAHTA), NIH 
database (USA), International Pleural Mesothelioma Program – WHOLIS (WHO Database), with 
the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, 
radiotherapy, review, investigational, drugs. Currently different targeted therapies and biologicals 
are under investigation for MPM. It is important that the molecular biologic research should 
first focus on mesothelioma-specific pathways and biomarkers in order to have more effective 
treatment options for this disease. The use of array technology will be certainly an implicit gain 
in the identification of new potential prognostic or biomarkers or important pathways in the 
MPM pathogenesis. Probably a central mesothelioma virtual tissue bank may contribute to 
the ultimate goal to identify druggable targets and to develop personalized treatment for the 
MPM patients.
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Palliative surgery
Debulking pleurectomy/decortication (P/D) can be defined as sig-
nificant but incomplete macroscopic clearance of pleural tumor. 
The objective of the operation is to relieve an entrapped lung by 
removing the visceral tumor cortex. Removal of the parietal tumor 
cortex may relieve a restrictive ventilatory deficit and reduce chest 
wall pain. The operative procedure needs to be further standard-
ized and may be performed by either open thoracotomy, but the 
closed video assisted thoracoscopic surgery (VATS) is preferred. 
There are series of retrospective studies which provide low grade 
evidence for P/D (Waller et al., 1995; Soysal et al., 1997; Martin-
Ucar et al., 2001; Halstead et al., 2005; Muirhead and O’Rourke, 
2007; Nakas et al., 2008).
Palliative chemotherapy
Two international randomized studies (Vogelzang et al., 2003; Van 
Meerbeeck et al., 2005) suggested that combination chemotherapy 
including cisplatin and an antifolate, either pemetrexed or ralti-
trexed, increases survival compared to single agent cisplatin. The 
median survival observed in both studies showed an improve-
ment of 2.6–2.8 months for the combination arm. Based on these 
two randomized phase III trials, it is now generally accepted to 
treat patients with MPM with a combination of an antifolate with 
IntroductIon
The etiology, epidemiology, diagnosis, prognosis, and management 
of MPM have recently been reviewed and guidelines have been 
issued (Stahel et al., 2009; Scherpereel et al., 2010). Malignant pleu-
ral mesothelioma (MPM) is a rare but aggressive neoplasm that 
arises from the mesothelial surfaces of the pleural cavity. MPM has 
a bad prognosis: median survival of untreated cases is 6–9 months 
with less than 5% 5-year survivors. Essential prognostic factors 
associated with better outcome are earlier stage and epithelioid 
histologic type (UICC, 2006). Additional prognostic factors are the 
presence of symptoms, performance status, age, gender, and weight 
loss. The prognostic value of asbestos exposure is controversial.
ManageMent of MPM: standard of care
Palliative radiotherapy
The aim of palliative radiotherapy is pain relief and may be consid-
ered in cases of painful chest wall infiltration or nodules (Ung et al., 
2006). Responses of over 60% have been seen, although the duration 
of response – a median of 2–3 months – is often disappointing. The 
optimum dose has not been shown and many of the series were 
small and retrospective. Palliative radiotherapy is more effective if 
bone erosion or subcutaneous masses are present and less for diffuse 
pain, dyspnoea, superior vena cava syndrome or for retreatment.
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3. Postoperative radiotherapy (PORT) with 54 Gray (Gy) to the 
hemithorax after EPP resulted in a local recurrence rate of 
13% and a 4% local-only recurrence rate (Rusch et al., 2001). 
Preliminary results of intensity-modulated radiotherapy 
(IMRT) in the adjuvant setting after EPP seemed particularly 
promising as they could provide good local control and pro-
tect organs at risk such as heart or liver (Ahamed et al., 2003). 
However, severe pulmonary toxicity has been reported in 
recent studies so that it should not be recommended outside 
of clinical trials (Allen et al., 2006; Rice et al., 2007).
4. The only published long-term survivors among resected 
mesothelioma patients have undergone radical surgery (EPP) 
as part of a combined modality treatment including postopera-
tive chemotherapy with or without PORT (Sugarbaker et al., 
1999; Flores et al., 2006). The preference for neo-adjuvant che-
motherapy is justified by its better compliance, lower rate of 
surgical morbidity, high rate of objective response, good rate 
of radical resections and the possibility to select the optimal 
patients to be submitted to surgery. This approach was explo-
red first in a number of single institutional phase II studies 
with promising results (Weder et al., 2004; De Perrot et al., 
2009). A number of multicentre prospective phase II trials 
exploring the feasibility of a multimodality approach in highly 
selected patients, combining neo-adjuvant chemotherapy, fol-
lowed by EPP and PORT have demonstrated a similar median 
survival of 17–20 months (Table 1; Weder et al., 2007; Krug 
et al., 2009; Van Schil et al., 2010). At least 2 more multicentre 
phase II trials addressing the same issues are on-going.
InvestIgatIonal drug aPProaches
new antIfolates, PlatInuM analogs, and new thIrd 
generatIon cytotoxIc agents
The cytotoxic activity of antifolates is mainly due to their ability to 
inhibit several different folate-dependent enzymes involved in DNA 
synthesis. The key enzyme in the folate metabolism of MPM is thymi-
dylate synthase (TS). Low TS protein levels are predictive of improved 
overall survival in pemetrexed treated patiens with MPM (Righi et al., 
2010). Glycinamide ribonucleotide formyl transferase (GARFT) and 
dihydrofolate reductase (DHFR) might also be of importance. The 
most widely used antifolate in the treatment of MPM is Pemetrexed. 
Pemetrexed is a third generation antifolate and primarily an inhibitor 
of TS with also potent, but lesser, inhibition of GARFT and DHFR. It 
has a substrate specific high-affinity transport route in mesothelioma 
cell lines, favoring its use in MPM (Wang et al., 2002).
Novel antifolates include nolatrexed, an oral specific TS inhibi-
tor that was developed using protein structure-based drug design, 
primarily for the treatment of hepatocellular carcinoma. Only one 
patient with MPM was included in a phase I trial and its develop-
ment was halted after a negative phase III trial in hepatocellular 
carcinoma (Hughes et al., 1999; Gish et al., 2007). New DHFR 
inhibitors such as pralatrexate, talotrexin, and previtrexed have 
also been developed, but at the moment only pralatrexate has been 
tested in MPM. In a phase II study it showed no activity as an sin-
gle agent (Krug et al., 2007). AG 2037 is a GARFT inhibitor being 
evaluated for its activity in NSCLC and colorectal cancer (Webber 
et al., 1996). No trials have been conducted for its effect in MPM.
platinum. Other cisplatin-based combinations have also produced 
interesting response rates of 20–30% in phase II studies: etoposide, 
epirubicin, gemcitabine, vinorelbine, or methotrexate (Berghmans 
et al., 2003; Ellis et al., 2006). The combination of carboplatin with 
pemetrexed shows outcome data similar to the ones obtained with 
cisplatin and pemetrexed (Ceresoli et al., 2008; Santoro et al., 2008). 
Few things we do not really know about cisplatin/pemetrexed 
include: when to start therapy, when to stop (maintenance?) and 
the role of the predictive markers TS and ERCC-1. In second line, 
no randomized trial has yet demonstrated any benefit in overall 
survival or quality of life. In the last two decades, only seven phase 
II studies (Harvey et al., 1984; Sorensen et al., 1985, 2007; Giaccone 
et al., 2002a; Porta et al., 2005; Fennell et al., 2007; Zucali et al., 2008) 
have addressed this question but failed to come to any recommen-
dation. Some promising activity was noted with pemetrexed alone 
(Sorensen et al., 2007) and a combination of cisplatin, irinotecan, 
and mitomycin (Fennell et al., 2007). In a phase III study, patients 
with progressive disease were randomized to best supportive care 
(BSC) or second line pemetrexed single agent (Jassem et al., 2008). 
Time to progression was significantly longer in the pemetrexed arm 
but there was no improvement in overall survival. This might be 
due to significantly more patients in the BSC arm receiving post 
discontinuation chemotherapy with pemetrexed compared with 
patients randomized in the pemetrexed arm. In the case of recurrent 
disease it is recommended to include patients in clinical studies. 
Patients showing an objective and symptomatic response can be 
rechallenged with pemetrexed.
Radical treatment
1. Radiation therapy to the full hemithorax is limited by critical 
organs such as the lung, the liver and heart most particularly, 
but also the spinal cord and the esophagus. Therefore it is dif-
ficult to administer a total dose more than 54 Gy to such a 
large volume. Therefore, sophisticated treatment techniques, 
oriented by surgeon’s and pathologist’s findings, are needed 
(Maasilta, 1991; Senan, 2003). Radical radiotherapy has never 
been compared to chemotherapy or surgery or to BSC (as 
part of combination therapy) in a prospective, randomized 
trial and no data exist supporting one or the other treatment 
(Chapman et al., 2006).
2. Radical surgery may be defined as an attempt to remove all 
macroscopic tumor from the hemithorax. These objectives are 
usually achieved by extrapleural pneumonectomy (EPP) with 
an en bloc resection of lung, visceral and parietal pleura, and 
ipsilateral hemi-pericardium and hemi-diaphragm, followed 
by pericardial and diaphragmatic reconstruction with prosthe-
tic material (usually Gore-Tex™). Operative mortality has fal-
len to an acceptable level of around 5% in experienced centers, 
but morbidity remains high at around 50% (Sugarbaker et al., 
2004; Opitz et al., 2006). Older literature indicates that surgery 
alone for MPM is not curative since no oncological resection 
margins can be obtained. The pleural lining, especially on the 
pericardium and mediastinum cannot be resected with a 1 to 
2-cm margin and therefore all surgical procedures are conside-
red R1 resections (Sugarbaker, 2006) and high local recurrence 
rates are the rule (Baldini et al., 1997) and this observation is 
therefore the rationale for combined modality therapy.
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In phase II trials of small cell lung cancer, it showed superior 
response rates compared to the topoisomerase I inhibitor topotecan 
(Jotte et al., 2010). Anthracyclines have shown activity in MPM, 
making amrubicin a promising future candidate for the treatment 
of MPM.
Trabectedin (also known as ecteinascidin 743 or ET-743) is a 
tetrahydroisoquinoline alkaloid isolated from a marine tunicate 
growing in mangrove roots. It is effective in metastatic soft tissue 
sarcoma. A Phase II Study is completed, but the data have not yet 
been published (Anonymous, n.d. f).
Alanosine (also called SDX-102) is an antimetabolite. It failed 
to show objective responses in a phase II trial including 16 patients 
with MPM (Kindler et al., 2009).
Most cancer cells are dependent on the G2 checkpoint to sur-
vive with DNA damage. The stable peptide CBP501 shows selective 
G2 checkpoint abrogation, with activity in various tumor models, 
alone and combined with DNA damaging agents. A phase I/II trial 
of CPB501 combined with cisplatin and pemetrexed is recruiting 
patients. The phase II part will evaluate full-dose cisplatin and 
pemetrexed combined with CBP501 (at the maximum tolerated 
dose, MTD determined in the phase I part) in previously untreated, 
unresectable MPM patients (Anonymous, n.d. e).
BIologIcals and targeted theraPIes
Recent pharmaceutical developments have focused on the identifi-
cation and inhibition of molecular pathways involved in the growth 
and progression of MPM. A number of novel agents have been or 
are being evaluated, including drugs targeted against the epidermal 
growth factor, platelet derived growth factor, vascular endothelial 
growth factor, src kinase, histone deacetylase, the proteosome and 
mesothelin (Table 2).
The epidermal growth factor receptor (EGFR) is a receptor 
tyrosine kinase that is over-expressed in a variety of malignancies. 
Signaling through EGFR is associated with inhibition of apopto-
sis, with resistance to chemotherapy, and metastases. EGFR was 
observed to be over-expressed on immunohistochemistry (IHC) in a 
majority of epithelioid mesothelioma specimens (Dazzi et al., 1990). 
Based on these data, the CALGB conducted a phase II trial that 
Cisplatin and carboplatin are effective in MPM both as single 
agents and as a component of combination chemotherapy. The 
efficacy of these platinum analogs is limited by several (intrinsic 
and acquired) mechanisms of resistance, including impaired cel-
lular uptake, intracellular inactivation by thiols and enhanced DNA 
repair. New platinum analogs have been developed to overcome 
this platinum resistance, though no new small molecule platinum 
drug has entered clinical trials since 1999. AMD 473 is a platinum 
analog that is less susceptible to detoxification by intracellular thi-
ols. AMD 473 demonstrated no activity in phase II trials with a total 
of 41 previously treated mesothelioma patients (Giaccone et al., 
2002b). Other platinum analogs including picoplatin, satraplatin, 
lobaplatin, and nedaplatin showed lower levels of toxicity in phase 
I and II trials but have failed to demonstrate superior efficacy in 
MPM compared to the classical platinum analogs cisplatin and 
carboplatin (Kelland, 2007).
Vinca alkaloids have activity in MPM. Vinorelbine is active in 
first and second line treatment.
In a phase II trial the efficacy and activity of a regimen of 
carboplatin together with vinorelbine administered i.v. and 
orally was evaluated. The regimen was easy to administer and 
generally well tolerated without any toxic deaths in spite of the 
poor prognostic patient population and the median survival 
was in excess of 9 months. The regimen was considered equally 
active as the combination of cisplatin and vinorelbine (Sørensen 
et al., 2007).
In vitro and in vivo, resistance to the novel vinca alkaloid vinfl-
unine, develops less readily than to vinorelbine. In an phase II trial 
vinflunine achieved a response rate of 13.8% and a median survival 
of 10.8 months (Talbot et al., 2007).
Microtubule-stabilizing agents such as the taxanes have shown 
only modest activity in MPM. The epothilones, a novel class of 
microtubule-stabilizing agents, are being tested in breast cancer, 
melanoma, and renal cell carcinoma. In light of the limited effect 
of the taxanes, they have not been tested in MPM patients in phase 
II or III trials.
Amrubicin combines anthracycline activity and potent topoi-
somerase II inhibition.
Table 1 | Prospective multicentre phase II trials of radical multimodality treatment in early stage mesothelioma.
Variable SAKK-trial (Weder et al., 2007) US-trial (Krug et al., 2009) EORTC trial (Van Schil et al., 2010)
N/n institutions 61/6 77/9 59/11
Induction regimen Cis-gem × 3 Cis-pem × 4 Cis-pem × 3
Compliance to induction chemotherapy 95% 83% 93%
EPP 45 (74%) 54 (70%) 42 (74%)
Operative mortality 2.2% 7% 6.5%
PORT completed 36 (59%) 40 (52%) 37 (65%)
Median OS (ITT; range) 19.8 m 16.8 m 18.4 m
Median OS (PP) 23 m 29.1 m NA
Local relapse (% PP) NS 11 (28%) 6 (16%)
Median PFS (ITT) 13.5 m 10.1 m 13.9 m
Median overall treatment time (days; range) NS NS 184
NS, not stated; PORT, postoperative radiotherapy; ITT, intention to treat; PP, per protocol; EPP, extrapleural pneumonectomy; OS, overall survival; PFS, progression 
free survival.
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Table 2 | Targeted agents in MPM.
Compound Target Stage of development RR/MST Toxicity Reference
Gefitinib EGFR Phase II 4%/6.8 m Diarrhea, skin, nausea Govindan et al. (2005)
Erlotinib EGFR Phase II single agent 0% Skin, nausea, diarrhea Garland et al. (2007)
Phase II with 
bevacizumab
10 m Anonymous (2009e)
Cetuximab EGFR Phase II with cis/carbo 
and pemetrexed
– – Anonymous (2009b)
Imatinib PDGFR Phase II 0%/2–14.3 m Edema, nausea, 
diarrhea
Kumar-Singh et al. (1999); 
Millward et al. (2003), 
Villano et al. (2004), 
Mathy et al. (2005), Porta 
et al. (2007)
Phase II with gemcitabine – – Anonymous (2009a)
Phase I with cisplatin and 
pemetrexed
– – Anonymous (2009h)
Sorafenib KDR, Flt-4, PDGFR, Raf Phase II 4%/14.3 m Fatigue, hand, and 
foot-syndrome
Janne et al. (2007)
Phase I with doxorubicin 10.7 m Richly et al. (2006)
Phase II with doxorubicin Anonymous (2009j)
Vatalanib KDR, Flt-4, PDGFR, Raf Phase II 11%/10 m – Jahan et al. (2006)
Sunitinib Flt-1, KDR, Flt-4, PDGFR Phase II second line 15%/5.9 m high Anonymous (2009m)
Phase II first line – – Nowak et al. (2008)
Phase I platinum and pem – – Anonymous (2009c)
Cediranib (AZD2171) VEGFR, PDGFR, C-kit Phase II – – Anonymous (n.d. d)
Bevacizumab VEGF Phase II with cis and gem 15.6 m Hypertension, epistaxis Karrison et al. (2007)
Phase II with erlotinib – – Anonymous (2009e)
Phase II with cis and pem DCR at 6 m: 46/versus 
54%; PFS 9.2 m
Zalcman et al. (2010)
Thalidomide VEGF Phase II 0%/SD > 6 m: 28% 7.5 m Baas et al. (2005)
Phase II with cis/gem 14% Pavlakis et al. (2003)
Temsirolimus m-TOR Phase I 0% – Raymond et al. (2004)
Bortezomib Proteasome Phase II (second line) – – Anonymous (2009g)
Phase II with cisplatin 
(EORTC)
– – Anonymous (2009f)
Vorinostat HDAC Phase I 15% nausea, vomiting Krug et al. (2006)
Phase III – – Anonymous (2009l)
PXD101 HDAC Phase II (second line) – – Anonymous (2009i)
SS1P Mesothelin Phase I 12% edema,fatigue 
hypoalbuminemia
Hassan et al. (2007)
Phase II – – Zhang et al. (2006)
MORAb-009 Mesothelin Phase I – – Anonymous (2009d)
CRS-207 Mesothelin Phase I – – Anonymous (n.d. j)
GC1008 TGF-β Phase I – – Anonymous (2010)
Dasatanib Src Phase I (resectable) – – Anonymous (n.d. b)
Phase II (pretreated) – – Anonymous (n.d. a)
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with  cisplatin and gemcitabine with or without bevacizumab. The 
 treatment was tolerated well without any major toxicity. Nevertheless, 
there was no improved outcome with the addition of bevacizumab. 
The median progression free survival with and without the addition 
of bevacizumab, were 6.9 and 6.0 months, respectively. Although 
the median overall survival was numerically superior for bevaci-
zumab + chemotherapy (15.6 versus 14.7 months), this difference 
was not statistically significant. An exploratory subset analysis noted 
improved survival with bevacizumab-chemotherapy regimen in 
patients with low circulating levels of VEGF. The multicenter, ran-
domized phase II-III trial (MAPS) of cisplatin–pemetrexed with or 
without bevacizumab showed a DCR at 6 months of 46% versus 
54% for the bevacizumab arm. A promising PFS of 9.2 months was 
shown. Biomarker studies are on-going (Zalcman et al., 2010). Based 
on these results the IDMC recommended a phase III trial. An on-
going phase II study is addressing the activity of bevacizumab added 
to erlotinib in second line (Anonymous, 2009e).
Several small molecule inhibitors of the VEGF receptor tyros-
ine kinase have been tested in phase II studies. The multikinase 
inhibitor sorafenib inhibits the Ras/Raf/MEK/ERK and p38 signal-
ing pathways, VEGFR-2 and VEGFR-3, and members of the PDGF 
receptor family, PDGFRβ and c-Kit. Sorafenib was evaluated as 
monotherapy for recurrent MPM in a phase II study by the CALGB 
(Janne et al., 2007). Treatment was tolerated well, but the response 
rate of 4% did not meet the criteria for further evaluation of this 
agent as monotherapy. In a phase I study, one patient with MPM 
reported a partial response when sorafenib was combined with 
doxorubicin (Richly et al., 2006). This combination is currently 
under evaluation in a phase II study in MPM (Anonymous, 2009j).
PTK 787 (vatalanib), an aminophenazone derivative, is an inhib-
itor of all known VEGFRs and, at higher concentrations, of PDGFR 
and c-kit. In a Phase II study, the efficacy of vatalanib was studied 
and correlated the response to treatment with circulating serum lev-
els of VEGF, PDGF, and VEGF in chemonaive patients with MPM. 
RR was 11%, median OS 10 months, and PFS 4.1 months (Jahan 
et al., 2006). However, the study did not meet the prespecified end 
point of 3-month PFS rate. No correlation was observed between 
baseline VEGF or PDGF levels and response, PFS, or survival.
Sunitinib a tyrosine kinase inhibitor that acts on several tar-
gets, such as VEGFRs, PDGFRβ, and c-Kit is under evaluation in 
untreated MPM patients in a phase II study (Anonymous, 2009m) 
and has been tested in a Phase II study on patients who failed after 
a platinum plus pemetrexed regimen. A partial response in 15% of 
patients and stable disease in 55% of them was seen. The median 
OS was 5.9 months and the median TTP of 3.5 months. Moreover, 
the role of [18F]fluorodeoxyglucose positron emission tomography 
was also evaluated. A metabolic response was observed in 30% of 
patients without talc pleurodesis. Final results of this trial has been 
presented at ASCO 2010 and the authors concluded that activity was 
modest and toxicity high (Nowak et al., 2008). Sunitinib is under 
research in a phase I study in association with pemetrexed/cisplatin 
and pemetrexed/carboplatin and pemetrexed (Anonymous, 2009c).
Other VEGF tyrosine kinase inhibitors that are currently under 
evaluation include cediranib and pazopanib. AZD2171 (cediranib 
maleate), an indole–ether quinazoline derivative that acts with all 
three VEGFRs, with PDGFR and c-kit, is being evaluated in a Phase 
II study (Anonymous, n.d. d).
evaluated the role of gefitinib in the treatment of MPM (Govindan 
et al., 2005). No objective responses were reported and the regimen 
was not deemed suitable for further evaluation. Erlotinib, another 
EGFR inhibitor, was also evaluated in a phase II study for patients 
with MPM (Garland et al., 2007). No objective responses were seen 
despite a high rate of patients with EGFR-expressing tumors in 
the study. A possible explanation of absence of significant benefit 
from using EGFR-TKIs could be due to the absence of activating 
somatic mutation in EGFR-TKI domain that is strongly predictive of 
response to EGFR-TKIs (Cortese et al., 2006). Cetuximab, a mono-
clonal antibody against the EGF receptor is currently investigated 
in a phase II study in combination with platinum and pemetrexed 
(Anonymous, 2009b). Another Her-family member, ErbB-2 or 
Her2/neu is expressed in 97% of mesothelioma specimens on IHC. 
However, the ErbB-2 gene does not appear to be amplified and data 
from breast cancer studies suggest that specific ErbB-2 inhibitors 
may not be effective in the absence of amplification.
Findings derived from clinical and preclinical studies suggest 
that angiogenesis may be an important process in the pathogenesis 
of MPM. VEGFs and their receptors are over-expressed in MPM 
tissue, cell lines, pleural effusion and non-malignant mesothelial 
specimens and effusions (Kumar-Singh et al., 1999; Strizzi et al., 
2001). Circulating VEGF and high microvasculature density sig-
nificantly correlate with worse prognosis (Edwards et al., 2001). 
Angiogenesis allows the formation of new blood vessel essential 
for tumor growth. The first findings that linked mesothelioma and 
angiogenesis were reported by Branchaud et al. (1989). Recent data 
suggest the existence of relationship between SV40 and VEGF in 
MPM. In mesothelial cell cultures SV40 positive the levels of VEGF 
were significantly higher. Mesothelial cell transfected with SV40 or 
only with SV40 Tag antigen releases great amount of VEGF proteins 
and mRNA that leads to cell line proliferation. The inactivation of 
VEGF signal transduction pathway abolished this proliferation. 
Ligand–receptor interaction induces the activation of the tyrosine 
kinase domain of the VEGFRs, which leads to the activation of 
intracellular signal transduction pathways, such as the Raf/MEK/
extracellular signal-regulated kinase (ERK) and the PI3K/AKT. 
VEGFR-1 regulates positively the angiogenesis and is thought to 
be important for endothelial cell migration and differentiation. 
VEGFR-2 mediates most downstream effects of VEGF-A, includ-
ing vascular permeability, endothelial cell proliferation, invasion, 
migration, and survival. VEGFR-3 is involved in lymphangiogen-
esis, and its expression has been associated with the dissemination 
of tumor cells to regional lymph nodes. Proteins involved in regulat-
ing the angiogenic process have been implicated in the prognosis of 
MPM and can be indirectly assessed using immunohistochemistry 
and micro-vessel counting. Studies have indicated that increased 
micro-vessel density is associated with a poor outcome (Edwards 
et al., 2001). VEGF, the VEGF receptors (VEGFRs) flt-1 (VEGFR-1), 
KDR (VEGFR-2), and VEGFC and its cognate receptor VEGFR-3 
have been shown to be co-expressed in MPM (Ohta et al., 1999; 
Strizzi et al., 2001). Both VEGF and VEGFC function as autocrine 
growth factors for the development of MPM.
A randomized phase II study was conducted in patients with 
advanced MPM to evaluate whether the addition of bevacizumab, 
a monoclonal antibody against VEGFR, can enhance the efficacy 
of chemotherapy (Karrison et al., 2007). Patients were treated 
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play a role in regulating normal cell differentiation, apoptosis, and 
proliferation. Therefore, both histone and non-histone protein-
mediated effects of HDAC inhibitors are thought to be responsible 
for their anticancer effects (Deroanne et al., 2002). Initial studies 
of vorinostat have demonstrated objective responses in patients 
with MPM. In the initial phase I studies with the oral formula-
tion of vorinostat, 13 patients with advanced MPM were included 
(Krug et al., 2006). Twelve out of these patients had received prior 
systemic chemotherapy for MPM. Two objective partial responses 
were reported and the treatment regimen was tolerated well. These 
data form the basis for a large randomized clinical trial to compare 
vorinostat to placebo in pretreated patients. The primary end point 
is overall survival (Anonymous, 2009l). The mechanistic aspects 
of the efficacy noted with vorinostat in MPM are unclear. Because 
inhibitors of thymidylate synthase (TS) have demonstrated activity 
in MPM, it is conceivable that repression of TS and cytidine triphos-
phate synthetase by HDAC inhibitors could play a role. Another 
mechanism may be the induction of apoptosis, which has been 
demonstrated with preclinical studies of sodium butyrate, a HDAC 
inhibitor, in mesothelioma cell lines. HDAC inhibitors have also 
been shown to block angiogenic signaling by inhibiting VEGF-
induced expression of VEGF receptors. Another HDAC inhibitor, 
belinostat, is being evaluated in a Phase II study as a second line 
therapy (Anonymous, 2009i).
The proteasome inhibitor bortezomib inhibits nuclear factor-
kappa B and up-regulates pro-apoptotic BH3 proteins (Fennell 
et al., 2008). Proteasome inhibition induces apoptosis of mesothe-
lioma cells in vivo and in vitro (Gordon et al., 2007; Sartore-Bianchi 
et al., 2007). On the basis of promising preclinical data, two phase 
II trials of bortezomib have been initiated in Europe. One trial is 
exploring single agent activity in the second line setting and in 
patients with a performance status of 2 in the first-line setting 
(Anonymous, 2009g). The second trial, conducted by the EORTC, 
has explored this agent in combination with cisplatin in the first-
line setting (Anonymous, 2009f).
Other angiogenic growth factors expressed in this disease include 
transforming growth factorβ, FGF1, FGF2, thrombospondin 1, 
methionine amino-peptidases, interleukin (IL)-6 and IL-8. High 
levels of VEGF and FGF2 or co-expression of TGFβ, VEGF, FGF1, 
and FGF2 have been found to be associated with a poor outcome. 
MPM exhibits high levels of expression of the surrogate marker 
of hypoxia, hypoxia-inducible factor 1α (Klabatsa et al., 2006).
Blockade of TGF-β is an new approach for mesothelioma.
GC1008 is a human IgG4 kappa monoclonal antibody capable of 
neutralizing all mammalian isoforms of TGF-β (i.e., β1, β2, and 
β3). GC1008 is a high-affinity antibody with dissociation constants 
(Kds) of 1.8, 2.8, and 1.4 nM for TGF1, 2, and 3, respectively. The 
anti-TGF Monoclonal Antibody GC1008 is currently investigated 
in relapsed MPM (Anonymous, 2010).
Dasatinib, a Src inhibitor, is currently evaluated in a phase II 
trial in pretreated patients and in another trial in patients with 
resectable mesothelioma (Anonymous, 2010; Anonymous n.d. a).
MesothelIn targeted IMMunotheraPy
Mesothelin is a differentiation antigen whose expression in normal 
human tissues is limited to mesothelial cells lining the pleura, peri-
cardium, and peritoneum. However, mesothelin is highly expressed 
Thalidomide, a broadly targeted agent, inhibits angiogenesis 
mediated by VEGF, basic fibroblast growth factor (FGF) and TGF-
α. A Phase II study evaluated the efficacy of thalidomide in 40 
patients who have mesothelioma, of whom 50% had received pre-
vious chemotherapy. Disease stabilization for longer than 6 months 
was reported in 27.5% of the patients (Baas et al., 2005). Pavlakis 
et al. (2003) evaluated thalidomide alone or in combination with 
gemcitabine/cisplatin in two parallel non-randomized phase II 
studies. Single agent thalidomide was administered to 22 patients 
who were not considered suitable for chemotherapy nor progressed 
during treatment with antineoplastic drugs, whereas gemcitabine 
plus cisplatin was given with thalidomide to 16 chemotherapy-naive 
patients. Disease stabilization for longer than 6 months was observed 
in 25% of the patients who received single agent thalidomide, while 
in the combination arm, a partial response rate of 14% was reported, 
and 32% of these patients achieved disease stabilization for longer 
than 6 months. Moreover, a non-significant trend suggested that 
higher baseline levels of VEGF correlated with a shorter survival in 
both arms. However, when administered as consolidation following 
first-line platinum–antifolate based chemotherapy, thalidomide did 
not improve outcome when compared to placebo (Baas et al., 2011).
Imatinib is a highly selective inhibitor of the bcr/abl mutated 
tyrosine kinase, as well as of both c-kit and PDGFRs. Several Phase 
II studies have been conducted with imatinib mesylate in MPM 
refractory to chemotherapy or chemonaive patients, but negative 
results were reported (Kumar-Singh et al., 1999; Millward et al., 
2003; Villano et al., 2004; Mathy et al., 2005; Porta et al., 2007). 
In vitro and in vivo experiments demonstrated that STI-571 can 
cause MPM cell apoptosis and death through inhibition of the 
AKT/PI3K pathway and that it can also enhances MPM sensitivity 
to gemcitabine or pemetrexed (Bertino et al., 2007). Patients with 
MPM are currently being enrolled in a Phase I study of imatinib 
combined with cisplatin and pemetrexed (Anonymous, 2009h) and 
in a phase II study in association with gemcitabine to evaluate the 
efficacy of these compounds (Anonymous, 2009a).
Rapamycin, a natural macrolide approved as immunosuppressor, 
was found to exert anti-proliferative effects by inhibition of serine/
threonine kinase, which in mammals is called mammalian target 
of rapamycin (m-TOR). Synthetic derivatives or “rapalogs” have 
been developed to improve the pharmacological properties of rapa-
mycin: everolimus, temsirolimus, and deforolimus. Temsirolimus 
was evaluated in a phase I study of dose-escalation and no tumor 
response in patients with MPM was observed (Raymond et al., 
2004).
Histone deacetylase (HDAC) inhibitors are novel anticancer 
agents that act by a variety of mechanisms. Histones are the core-
proteins in the center of the DNA double helix. The histone proteins 
exist in either a non-acetylated transcriptional inactive configura-
tion or an acetylated state that is open to gene transcription. The 
dynamic equilibrium between the acetylated and non-acetylated 
forms is mediated by histone acetyltransferase and HDAC (Marks 
et al., 2001). Agents that inhibit HDAC have recently demonstrated 
promising anticancer activity in early phase clinical trials. Vorinostat 
is a small molecule inhibitor of HDAC that is approved by the FDA 
for the treatment of advanced, relapsed, or refractory cutaneous 
T-cell lymphoma. In addition to its inhibitory effect on HDAC, 
vorinostat also acetylates several key cell signaling proteins that 
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patients with epithelial ovarian cancer when compared with a 
normal control population. Mesothelin-specific antibodies were 
present at a higher frequency in patients whose tumors had strong 
mesothelin expression by immunohistochemistry. These results 
suggest that the immunogenicity of mesothelin is associated with 
its high expression on the tumor cells and serologic recognition of 
mesothelin is cancer related. The presence of a mesothelin-specific 
B-cell response in a significant proportion of patients with meso-
thelin expressing tumors supports on-going efforts to use meso-
thelin as a therapeutic cancer vaccine. Several agents with activity 
in preclinical models are being developed to target mesothelin: a 
recombinant immunotoxin (SS1P), a humanized monoclonal anti-
body (MORab-009) and an attenuated Listeria vector that encodes 
human mesothelin (CRS-207).
SS1P is a recombinant immunotoxin consisting of an anti-meso-
thelin Fv linked to a truncated Pseudomonas exotoxin that mediates 
cell killing (Chowdhury et al., 1998; Chowdhury and Pastan, 1999). 
After binding to mesothelin, the immunotoxin is internalized via 
clathrin coated pits, undergoes processing in the endocytic com-
partment and the immunotoxin fragment containing the ADP-
ribosylation domain is transported to the endoplasmic reticulum 
and then translocated to the cytosol where it inhibits elongation 
factor-2 leading to inhibition of protein synthesis and ultimately 
cell death (Hassan et al., 2007). Recent studies have looked at the 
anti-tumor activity of SS1P in combination with radiation therapy 
or chemotherapy. Athymic nude mice bearing A431/K5 mesothelin 
expressing tumors were treated with radiation alone, SS1P alone or 
the two agents in combination (Chowdhury et al., 1998). The results 
of this study showed that mice treated with low-dose radiation and 
SS1P or high-dose radiation and SS1P had a statistically significant 
prolongation in time to tumor doubling or tripling compared with 
control, SS1P or radiation alone treated mice. Since radiation treat-
ment increased the cell surface expression of mesothelin, it is pos-
sible that the increased anti-tumor activity of SS1P in combination 
with radiation is partly due to enhanced mesothelin expression, 
making the cells more sensitive to SS1P treatment. Given the non-
overlapping toxicities and different modes of action of SS1P and 
chemotherapeutic agents, combining them could potentially result 
in increased anti-tumor activity in patients.
Two Phase I studies of SS1P have just been completed. These 
studies which were designed to test the safety, MTD, and pharma-
cokinetics of SS1P used two different strategies for SS1P admin-
istration. In one study SS1P was administered as an intravenous 
bolus infusion over 30 min (SS1P bolus infusion study) while as in 
the other study SS1P was given as a continuous i.v. infusion over 
10 days (SS1P continuous infusion study). Most common toxicities 
were similar for both the bolus infusion and continuous infusion 
including hypoalbuminemia, weight gain, edema, and fatigue. Of 
the 33 evaluable patients treated, four had minor responses, 19 
had stable disease (including two with resolution of ascites and 
died after 5 years after the therapy), while 10 had progressive dis-
ease (Hassan et al., 2007). Based on this study and in previously 
reported synergistic effects of SSP1 in combination with chemo-
therapy (Zhang et al., 2006), a phase II study is planned.
MORAb-009 is a high-affinity chimeric (mouse/human) mono-
clonal IgG1/κ with high-affinity and specificity for mesothelin. The 
heavy and light chain variable regions of mouse anti-mesothelin 
in several human cancers, including virtually all mesotheliomas 
and pancreatic adenocarcinomas, and approximately 70% of ovar-
ian cancers and 50% of lung adenocarcinomas. Mesothelin gene 
expression in human cancers has been studied using serial analysis 
of gene expression (SAGE) tag analysis. High mNA expression of 
mesothelin is found in mesothelioma, lung, ovarian, and pancreatic 
adenocarcinomas. In addition, immunohistochemistry has helped 
delineate the frequency and pattern of mesothelin protein expres-
sion in these tumors. These studies have been greatly facilitated by 
the commercial availability of a monoclonal antibody (mAb) 5B2 
(Novocastra, Newcastle-on-Tyne, UK) that can detect mesothe-
lin expression in paraffin embedded tissues. Mesothelin is highly 
expressed in epithelial malignant mesothelioma (Figure 1). In the 
original study by Chang et al. (1992), mesothelin expression was 
evaluated by mAb-K1 using frozen section tissues of patients with 
malignant mesothelioma. Out of the 23 pleural mesothelioma sam-
ples analyzed all 15 epithelial mesothelioma samples had mesothe-
lin expression, while 4 sarcomatous mesotheliomas were negative. 
In the four samples with biphasic mesothelioma, only the epithelial 
component stained for mesothelin. Mesothelin expression in paraf-
fin embedded mesothelioma tissue samples was studied by Ordonez 
(2003) using mAb 5B2. Out of the 55 mesothelioma specimens (44 
epithelioid, three biphasic, and eight sarcomatoid) studied, meso-
thelin reactivity was noted in all epithelioid mesotheliomas and 
the epithelial component of biphasic mesotheliomas and none of 
the sarcomatous mesotheliomas expressed mesothelin. Although 
mesothelin is not a specific marker for mesothelioma a negative 
mesothelin immunostain strongly argues against the diagnosis of 
epithelioid mesothelioma (Ordanez, 2007). To determine whether 
a spontaneous humoral B-cell response to mesothelin is present 
in patients with mesothelin expressing cancers Ho et al. (2005) 
used a sensitive enzyme-linked immunosorbent assay (ELISA) 
to detect mesothelin-specific IgG antibodies in serum of patients 
with advanced mesothelioma and ovarian cancer. Elevated lev-
els of mesothelin-specific antibodies were detected in the sera of 
27 of 69 (39%) patients with mesothelioma and 10 of 24 (42%) 
FIgURE 1 | Mesothelin expression detected by IHC in tissue specimens of 
patients with MPM (×250). 
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patients with MPM after completion of combined modality therapy 
is on-going (Anonymous, n.d. h). Mesothelin as tumor vaccine has 
been described in the previous section.
dendrItIc cell Based IMMunotheraPy
Immunotherapy is a promising approach in the treatment of can-
cer. It tries to harness the potency and specificity of the immune 
system to attack cancer cells. The aim is a non-toxic treatment with 
minor side-effects and a long-lasting immunological memory. One 
approach of immunotherapy uses dendritic cells (DC) to present 
tumor-associated antigens (TAA) and thereby generate tumor-
specific immunity (Steinman and Dhodapkar, 2001; Banchereau 
and Palucka, 2005) DC are extremely potent antigen-presenting 
cells specialized for inducing activation and proliferation of CD8+ 
cytotoxic T lymphocytes (CTL) and helper CD4+ lymphocytes. 
Hegmans et al. (2005) demonstrated in a murine model that immu-
notherapy, using pulsed DC, may emerge as a powerful tool to 
control mesothelioma outgrowth. They showed that mesothelioma 
is infiltrated by immune effector cells but also contains cytokines 
and regulatory T-cells that suppress an efficient immune response. 
Immunotherapy of mesothelioma might be more effective when 
combined with drugs that eliminate or control regulatory T-cells 
(Hegmans et al., 2006). They have also demonstrated that the effi-
cacy of immunotherapy was dependent on the tumor load. The 
most beneficial effects were established at early stages of tumor 
development. This is in agreement with the current knowledge 
of the effect of immunotherapy in other tumor types (Cranmer 
et al., 2004). On the basis of these preclinical animal studies, a 
clinical trial in which autologous tumor lysate–pulsed DC were 
administered intra-dermally and intravenously in mesothelioma 
patients after cyto-reductive therapy with chemotherapy is now 
completed. Patients received 50 × 106 mature DC pulsed with tumor 
lysate and keyhole limpet hemocyanin (KLH) every 2 weeks for a 
total of three injections. The administration of DCs loaded with 
autologous tumor cell lysate to patients was safe. Local skin reac-
tions were seen at the site of the intradermal injection suggesting 
that some form of immunity was induced. There was no clinical 
or radiological evidence of any autoimmunity. Distinct immuno-
logical responses to the surrogate marker KLH were induced by 
the vaccinations, both in vitro as in vivo. Importantly, anti-tumor 
cytotoxicity activity against autologous tumor cells was measured 
in the blood of patients. An increase in systemic CTL activity was 
seen in a subset of treated patients (4 out of 6). Multiple vaccina-
tions were necessary as the increase in CTL activity was seen only 
after 3 vaccinations for most of the patients in this assay. DC loaded 
with autologous tumor cell lysate administrated to patients was 
considered safe and feasible and no adverse effects were observed. 
Anti-tumor immune responses were detected in a few patients 
with mesothelioma after DC-immunotherapy.
 
Whether this has a 
beneficial effect in improving survival will be the subject in succes-
sive studies. Influencing the immunosuppressive cells (Tregs, M2 
macrophages, and MDSC), cells abundantly present in the tumor 
environment, and their subsequent effect on DC-mediated
 
anti-
tumor responses, seems of critical importance for future clinical 
trials. Also other sources of antigens to pulse DC must be inves-
tigated to make DC-immunotherapy more accessible for larger 
numbers of patients to perform comparative studies (Figure 2).
scFv (obtained by panning on mesothelin-positive cells a phage 
display library made from splenic mRNA of a mouse immunized 
with mesothelin cDNA) were grafted in frame with human IgG1 
and κ constant regions. Since MORAb-009 is a chimeric antibody 
containing only the mouse sequences that recognize human meso-
thelin, it should be less immunogenic and allow repeated adminis-
tration to patients. Laboratory studies show that MORAb-009 kills 
mesothelin expressing cell lines via antibody dependent cellular 
cytoxicity (ADCC) and in addition it inhibits the binding of meso-
thelin to CA-125. Based on these preclinical studies a Phase I clinical 
trial of MORAb-009 has been completed (Anonymous, 2009d).
The rationale for mesothelin as a tumor vaccine is based on 
studies showing that mesothelin can elicit a strong CD8+ T-cell 
response in patients (Thomas et al., 2004). One of the mesothe-
lin cancer vaccines in advanced stages of clinical development is 
CRS-207 (Lm∆actA/∆inlB/hMeso). This vaccine utilizes a live-
attenuated strain of the bacterium Listeria monocytogenes (Lm), 
a facultative intracellular bacterium, as the vector 40 (Brockstedt 
et al., 2004). The engineered vector CRS-100, has deletions of the 
two genes that encode the virulence determinants actA and interna-
lin B (inlB), which results in a greater than 1000-fold decrease in 
virulence compared to the wild type Lm. CRS-207 is a live-atten-
uated Lm vaccine strain based on CRS-100 that encodes human 
mesothelin. Preclinical studies show that CRS-207 elicits human 
 mesothelin-specific CD4+/CD8+ immunity in mice and in cyn-
omolgus monkeys and exhibits therapeutic efficacy in tumor bear-
ing mice (Giedlin et al., 2007). A Phase I clinical trial of CRS-207 
for the treatment of patients with mesothelin expressing cancers 
is on-going (Anonymous, n.d. j). The utility of mesothelin as a 
tumor vaccine came from a clinical trial conducted by Jaffe and 
colleagues that involved vaccination of pancreatic cancer patients 
with GM-CSF transduced pancreatic cancer cell lines (Jaffee et al., 
2001). Out of the 14 patients treated on this study three developed 
a post-vaccination delayed-type hypersensitivity (DTH) response 
to the autologous tumor, that was associated with prolonged sur-
vival (Yokokawa et al., 2005). In another vaccine study, T-cell lines 
derived from the native or the agonist mesothelin epitope were 
shown to lyse mesothelin expressing and HLA-2 positive pancre-
atic cancer, ovarian cancer, and mesothelioma cell lines (Yokokawa 
et al., 2005). All these studies support the potential utility of meso-
thelin in peptide and/or vector-mediated immunotherapy proto-
cols for the treatment of cancers that highly express mesothelin.
vaccIne aPProaches
Vaccine approaches are also under investigation for the treatment 
of MPM. Wilms tumor associated gene (WT)-1 is a transcription 
factor expressed in tissues of mesodermal origin during embryo-
genesis. Up-regulation of WT-1 has been linked with tumouri-
genesis of various malignancies including mesothelioma and is an 
attractive target for immunotherapy (May et al., 2007). Therefore, 
WT-1 peptide epitopes that stimulate T-cell immunity are currently 
under evaluation for the treatment of mesothelioma. Preliminary 
results from on-going studies have documented the safety of this 
vaccine. Interesting preliminary results were observed after admin-
istration of Mycobacterium vaccae in a limited number of patients. 
This needs to be confirmed before further exploring this treatment. 
A randomized study of adjuvant WT-1 analog peptide vaccine in 
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et al., 2010). A phase I, dose-escalation study of telomerase- specific 
oncolytic adenovirus, OBP-301, is currently underway in the United 
States to assess the treatment feasibility and to characterize its 
pharmacokinetics in patients with advanced solid tumors. Phase 
II studies of telomerase-specific virotherapy in MPM patients are 
warranted. An phase I intra-pleural gene transfer study for pleural 
mesothelioma (IFN-alfa, SCH 721015, Ad.hIFN-a2b) is on-going 
(Anonymous, n.d. c). The effect of Ad. IFN is enhanced by combin-
ing with chemotherapy and phase I trials with this combination 
are in development.
InvestIgatIonal surgIcal aPProaches
In MPM, the role of surgery remains controversial and should be 
further explored. Although the multimodality treatment procedure 
seems feasible, overall treatment time is long and psychological 
distress is considerable. Subgroup analysis of a large Scandinavian 
phase II combination chemotherapy trial shows a median overall 
survival of 22 months in patients with good performance status, 
epithelioid subtype, stage I–II and aged 70 years or less, equiva-
lent to survival in patients subjected to multimodality treatment 
(Hillerdal et al., 2008). These findings stress the importance of a 
large prospective multicentre, in which operable patients with early 
gene theraPy
Malignant pleural mesothelioma represents a good potential target 
disease for gene therapy. The disease is localized until late, is eas-
ily accessible, current therapies are inadequate and there is some 
evidence of immune responsiveness. Clinical trials of patients with 
MPM have established the safety of the intra-pleural delivery of 
replication-deficient adenoviral vectors expressing the suicide gene, 
herpes simplex thymidine kinase, followed by the administration 
of ganciclovir, an antiviral drug. Some evidence indicates that 
this approach induces an effective anti-tumor immune response 
(Sterman et al., 1998, 2005). Moreover, intra-pleural interferon-β 
gene transfer with a replication-defective adenoviral vector may 
potentially be a useful approach for the generation of anti-tumor 
immune responses in MPM patients (Sterman et al., 2007). A sig-
nificant obstacle to these approaches is the limited distribution of 
the non-replicative vectors within the tumor mass, even after direct 
intra-tumoral administration. Therefore, more efficient strategies 
for the virus to spread within tumors may be required to increase 
the clinical benefit. In a recent study, it was shown that intrathoracic 
administration of telomerase-specific oncolytic viruses induced 
significant anti-tumor effects against both pre-established and 
established pleural dissemination of human MPM (Watanabe 
FIgURE 2 | A general workflow for the production of autologous dendritic 
cell vaccines for cancer immunotherapy. Monocytes, harvested from a 
leukapheresis, are differentiated in vitro under GMP-conditions into immature 
dendritic cells. The prototypical cytokines used for the generation of monocyte-
derived DCs are GM-CSF and IL-4. Immature DCs can subsequently be loaded 
with tumor-derived antigens using different approaches: DCs can phagocytose 
proteins from autologous tumor lysate or be electroporated with tumor-derived 
mRNA. When access to autologous tumor is too limiting, DCs can be loaded with 
allogeneic tumor proteins, peptides derived from putative tumor-associated 
antigens (TAAs), or transduced with viral vectors encoding TAAs. A crucial final 
step in the whole process is the activation/maturation of DCs, typically using 
Toll-like receptor ligands and/or a cocktail of activating cytokines. The resulting 
activated, tumor antigen-presenting DCs constitute the vaccine. After injection, 
DCs migrate to draining lymph nodes and activate tumor-specific cytotoxic T-cells.
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lack of concordance between the various predictive or prognostic 
studies (Gordon et al., 2003, 2005a; Pass et al., 2004; Glinsky et al., 
2005; Lopez-Rios et al., 2006) Nevertheless, several of the genes 
identified in these predictive array studies have also shown up in 
other MPM array studies. Meta-analysis of the different mesothe-
lioma studies may provide more robust prognostic genes which 
could be subsequently validated.
One emerging subset of genes which has been shown to be 
altered in mesothelioma concerns the insulin-like growth factor 
axis (Lee et al., 1993). With microarray analysis, several members 
of this axis have also been shown to be altered confirming the 
importance of this pathway in mesothelioma. Two commonly 
down-regulated genes from the IGF-axis in mesothelioma are 
IGFB-4 and IGFBP-5 (Kettunen et al., 2004), mainly over-
expressed genes include IGFBP-2, IGFBP-3, IGFBP-7/MAC25, and 
an exon specific isoform of IGF-I (IGF-I, exon 1A; Hoang et al., 
2004; Mohr et al., 2004; Gordon et al., 2005b; Anonymous, n.d. g) 
be noted that IGFBP-3 is another gene whose overexpression has 
also been linked to poor outcome tumors (Gordon et al., 2005b) 
indicating that a comprehensive analysis of the IGFBP family may 
have clinical value in MPM. A Phase II Study of IMC-A12, an 
antibody that is designed to block the effects of a protein called 
Type I Insulin-Like Growth Factor (IGF-1R), in patients with 
mesothelioma who have been previously treated with chemo-
therapy is on-going (Anonymous, n.d. g).
conclusIon
The last decade has seen some important changes in the man-
agement of mesothelioma. We now have active first-line chemo-
therapy available, which will not only moderately increase survival 
but will also help in relieving symptoms. But most of patients 
will have relapse after first-line chemotherapy and their survival 
is poor. The molecular biologic research should focus on meso-
thelioma-specific pathways and biomarkers; this is the only way 
to move forward and to explore novel, more active therapeutic 
options and better treatments for this disease. A small propor-
tion of patients might benefit from more aggressive (surgical) 
interventions with radical or even curative intent. It is our duty 
as physicians to inform our patients about all treatment options 
available but also to protect them from potential harmful or useless 
therapies. As with any rare disease, referral of the patients with 
MPM to a center with extensive experience and expertise with this 
disease is recommended to enhance the probability of accruing 
these patients into clinical trials.
Recent progress has reshaped the clinical landscape in the treat-
ment of MPM. We have now more effective chemotherapy and from 
current evidence, it is clear that histone deacetylase inhibitors repre-
sent a potentially new treatment modality in MPM. Among current 
investigational drugs, mesothelin targeted therapies, dendritic cell 
based immunotherapy, and gene therapy hold promise and should 
be further explored. Despite these, actual treatment is still amenable 
to improvement. Several factors have hampered the development of 
more effective regimens for mesothelioma. MPM is uncommon, is 
heterogeneous, staging is unreliable, response assessment is difficult 
and most drugs do not work. For the staging, the International 
Mesothelioma Interest Group are actually collaborating with the 
IASLC to include MPM in its proposals for the eighth edition of 
stage resectable MPM are randomly assigned to a surgical and a 
non-surgical management (Treasure et al., 2004). The feasibility of 
this approach has been explored in the UK MARS 1 trial, in which 
the randomization is between EPP followed by PORT and any pal-
liative treatment, including pleurodesis, following an induction 
treatment with chemotherapy (Treasure et al., 2009). The results of 
the feasibility part of this trial have recently been released and show 
no difference in survival between both treatment arms (Treasure 
et al., 2010). A large retrospective uncontrolled series reports that 
P/D might prolong survival as compared to EPP and that a less 
invasive procedure might hence be preferable in selected patients, 
provided it is standardized (Flores et al., 2008). In a systematic 
review of 1270 patients who had undergone lung-sparing surgery 
for mesothelioma (Teh et al., 2010), overall survival was comparable 
with the outcome reported in historical series including EPP. It is 
expected that a large European multicentre randomized trial will 
be conducted in the coming years, addressing the role of any tumor 
resection in MPM. Whether the latter will include EPP remains to 
be determined (Rusch, 2009).
InvestIgatIonal radIotheraPy aPProaches
As in NSCLC, the role of PORT in MPM is controversial and based 
on a single uncontrolled retrospective series. This additional value 
of PORT is being addressed in an on-going Swiss study, in which 
eligible patients are randomized after EPP between observation and 
hemi-thoracic PORT (Swiss Group for Clinical Cancer Research, 
2009). Pleural IMRT allows administering a radical dose of radio-
therapy to a MPM with intact lung (Rosenzweig et al., 2009). The 
role of IMRT with chemotherapy is presently being investigated in 
patients with irresectable disease (Anonymous, 2009k). Currently 
a study that looks at whether giving a short intense course of chest 
radiation just prior to surgery will sterilize these tumor cells and 
thus, avoid or reduce contamination of the areas outside the chest 
cavity is on-going. The investigators hypothesize that short neo-
adjuvant (pre-operative) hemi-thoracic IMRT, followed by imme-
diate planned EPP (± adjuvant chemotherapy) will reduce the risk 
of intra-operative seeding and reduce the incidence of distant meta-
static disease (Anonymous, n.d. i).
Another trial explores the use of new radiation technology, 
tomotherapy, to treat mesothelioma more aggressively than has 
been possible before. Tomotherapy’s ability to treat unusual shaped 
tumors, particularly when they are wrapped around sensitive nor-
mal tissues (the lung), enable higher doses of radiation to be used 
and this may improve its effectiveness (Anonymous, n.d. k).
An improved response has been seen in several studies where 
hyperthermia was added to radiotherapy. However, further inves-
tigation of this technique, which is not widely available, is required.
array technology In MesothelIoMa
With the advent of gene expression profiling frequent use of arrays 
has been carried out on MPM patient material, in attempts to iden-
tify profiles which may be predictive, prognostic or give informa-
tion on treatment response (predictive of personalized therapy). 
Other groups have attempted to use gene expression microarrays to 
identify potential MPM biomarkers or important pathways which 
may be important for MPM pathogenesis. One of the problems 
identified with the use of array technology in MPM, has been the 
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